Drug repurposing to target p53 protein family for improved therapy in the relapsed TP53 and EGFR mutated lung cancer
2020/39/B/NZ7/00757
Keywords
Descriptors
- NZ7_014: Farmacja, farmakoterapia, farmakologia
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Warszawski Uniwersytet Medyczny
Voivodeship: mazowieckie
Principal investigator (from the host institution)
dr hab. Alicja Elżbieta Chrzanowska
Number of co-investigators in the project: 4
Call
OPUS 20 – announced on 2020-09-15
- Amount awarded
- 2 589 600 PLN
- Project start date
- 2021-12-15
- Project end date
- 2026-12-14
- Project duration
- 60 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
The Therapeutic Potential of the Restoration of the p53 Protein Family Members in EGFR-Mutated Lung Cancer
- Authors:
- Fregni M, Ciribilli Y, Zawacka-Pankau JE.
- Academic press:
- Int J Mol Sci. (year: 2022, volume: 23(13):7213, pages: 20), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/ijms23137213 – link to the publication